Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Panelists discuss how they incorporate nivolumab into clinical practice, highlighting specific patient characteristics, biomarkers, and disease features that predict favorable responses to this immunotherapy agent.

EP: 1.Esophageal/Gastric Adenocarcinoma Standard of Care

Now Viewing

EP: 2.Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

EP: 3.Gastric Adenocarcinoma: Current Treatment Landscape

EP: 4.Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

EP: 5.Second-Line Treatment for Gastric Adenocarcinoma

Recent Videos